

COVID-19: Weekly Round-Up

27 April - 1 May 2020

IN BRIEF

- Global equities close out April with the best monthly performance in decades, as markets look beyond the near-term corporate and economic news flow.
- As lock-down exit plans from Italy and others give encouragement, Eurozone tensions re-emerge, as European Central Bank disappoints markets' hopes for additional stimulus,
- Risk appetite is buoyed on both sides of the Atlantic as US drug company Gilead Sciences announces positive success in the early trials of Remdesivir.

OUR VIEW

Monday

Risk sentiment ended last week on a more positive note. The decision by the credit rating agency S&P to keep Italy's investment grade credit rating static and not downgrade the coronavirus-stricken economy gave some much needed breathing room to European assets and boosted US equities late in the session. This decision undoubtedly aided risk sentiment, however, it put EU and Eurozone leaders under less pressure to coordinate support which may be a more substantial negative in the longer term.

Tuesday

Global equities rallied on Monday despite relatively little corporate or economic news flow. The focus was on expectations that US states could reopen sooner rather than later as well as a recognition that many major European economies, such as France and Spain, start to lay out their strategies for a staggered return to work. West Texas Intermediate (WTI) Oil slumped on Monday highlighting that the supply and demand imbalances

that laid the ground for last week's volatility had not been removed. However, despite the oil price volatility, markets were content to concentrate on the overall path of lockdown easing rather than the continued supply/demand imbalances in WTI Oil.

Wednesday

European markets performed strongly yesterday as more and more countries, including France, unveiled their plans to reopen their economies. The US market was unable to hold on to these gains however, and indices slipped ahead of the close as mixed earnings weighed on investor risk appetite. As more companies report Q1 earnings, weaker results from Ford was balanced by better numbers from Alphabet (Google). The continued relative stronger performance of Technology supports the sector as one of our two preferred themes, alongside healthcare.

Thursday

Risk appetite was buoyed on both sides of the Atlantic yesterday as Gilead Sciences announced positive success in the early trials of Remdesivir. A sign that drugs can have some effect on coronavirus is undoubtedly helping the market push higher. Turning to central banks, the US Federal Reserve (Fed) also confirmed that it would keep interest rates at the zero bound until the economic risks of coronavirus had passed. However, given the scale of the monetary intervention so far, it will be harder for the Fed to positively surprise from here. Increasingly the policy baton is being passed to governments as markets seek fiscal 'right-now' plans.

Friday

US equities in April have had their strongest month since 1987, that said the market ended the month yesterday with more of a whimper. A key factor driving this is the ECB meeting, whilst no major stimulus was expected, the decision to reduce financing costs for banks doesn't help deal with the elephant in the room which is the sovereign cost of coronavirus. This is a concern for markets as there's ongoing doubt that we will see a large-scale EU wide Recovery Fund providing non-repayable grants to member states. If we don't see coordinated fiscal burden sharing across the EU, this raises the risk that the Eurozone might underperform other regions globally in the post pandemic economy recovery.

FOLLOW US



You can keep up to date with our daily briefings on our website or, if you're short on time, we also post a 60 second video update from Edward Park, our Deputy CIO, every morning, before 9am, offering a quick market overview.

Available via [Twitter](#), [LinkedIn](#) and our [web page](#).

Important information

Investors should be aware that the price of investments and the income from them can go down as well as up and that neither is guaranteed. Past performance is not a reliable indicator of future results. Investors may not get back the amount invested. Changes in rates of exchange may have an adverse effect on the value, price or income of an investment. Investors should be aware of the additional risks associated with funds investing in emerging or developing markets.

The information in this document does not constitute advice or a recommendation and you should not make any investment decisions on the basis of it. This document is for the information of the recipient only and should not be reproduced, copied or made available to others.

Brooks Macdonald is a trading name of Brooks Macdonald Group plc used by various companies in the Brooks Macdonald group of companies.

Brooks Macdonald Asset Management Limited is regulated by the Financial Conduct Authority. Registered in England No 3417519. Registered office: 21 Lombard Street, London EC3V 9AH. Brooks Macdonald Asset Management (International) Limited is licensed and regulated by the Guernsey Financial Services Commission. Its Jersey Branch is licensed and regulated by the Jersey Financial Services Commission. Brooks Macdonald Asset Management (International) Limited is an authorised Financial Services Provider, regulated by the South African Financial Sector Conduct Authority. Registered in Guernsey No 47575. Registered office: First Floor, Royal Chambers, St. Julian's Avenue, St. Peter Port, Guernsey GY1 2HH.

More information about the Brooks Macdonald Group can be found at www.brooksmacdonald.com.